secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEXX LABORATORIES INC /DE (IDXX)
CIK:        0000874716
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0001157523-23-001588
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEXX Q3 revenue $916M (+9% reported); EPS $2.53; FY guidance updated to $3.635-$3.65B
--------------------------------------------------------------------------------

- Q3 revenue $916M (+9% reported, +8% organic) driven by CAG Diagnostics recurring revenue +10% reported (+9% organic).
- EPS $2.53, up 18% reported (16% comparable); operating margin 30.1% (expanded 100bps reported, 140bps comparable).
- FY2023 revenue guidance lowered to $3,635-$3,650M (7.9%-8.4% growth); EPS outlook raised to $9.74-$9.90 (midpoint +$0.05).
- Global premium instrument installed base grew 11% YoY; VetLab consumables revenue +11% organic.
- Water revenue +7% organic; Livestock/Poultry/Dairy revenue +2% organic; solid gains in U.S. offset international headwinds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874716/000115752323001588/0001157523-23-001588-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874716/000115752323001588/a53720791.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-001588

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer